ARTICLE | Regulation
FDA resumes CRL releases, citing ‘commitment to transparency’
New batch of complete response letters includes camrelizumab plus rivoceranib combo from Hengrui and Elevar
July 11, 2026 12:18 AM UTC
Just days after HHS confirmed that FDA had paused the release of complete response letters for unapproved drugs, the agency has released 16 CRLs.
Friday’s release underscores the Trump administration’s “steadfast commitment to transparency,” an HHS spokesperson told BioCentury. ...